Form 4: Mirum Pharmaceuticals CEO Exercises Stock Options and Acquires Shares

Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options to acquire 34,013 shares of common stock at a price of $2.936 per share on July 23, 2024.

Summary

• On July 23, 2024, Christopher Peetz, the CEO of Mirum Pharmaceuticals, exercised stock options.
• This transaction resulted in the acquisition of 34,013 shares of common stock at a price of $2.936 per share.
• Following the transaction, Mr. Peetz directly owns 126,783 shares and indirectly owns 208,570 shares through The Peetz Family Trust.
• The stock options were granted previously and vested over time, with the initial vesting occurring one year after November 5, 2018, and subsequent vesting in monthly installments.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The CEO exercising options could be seen as a positive sign, but it's not definitively bullish.

Positives

• The CEO's decision to exercise stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the CEO.

Key Dates